TwinRCT 3.0 Upgrade Boosts Phase 2 Trial Efficiency

Unlearn, a pioneering firm in the realm of AI-driven medical solutions, has unveiled the latest iteration of its innovative TwinRCT™ platform, TwinRCT 3.0. This technology employs digital representations, or "digital twins," of clinical trial participants to enhance the efficiency and effectiveness of trials. These twins are AI-generated models based on detailed patient data, which allow for more potent trials or the reduction of the control group size.

The upgraded TwinRCT 3.0 is now capable of integrating additional data from past clinical trials, thereby offering a stronger framework for Phase 2 trial assessments. Phase 2 trials are pivotal in the drug development pipeline, as they gauge the efficacy of a new drug. A trial with greater power at this stage is more likely to detect a treatment's impact, which is crucial for deciding whether to progress to the more costly and extensive Phase 3 trials. The conventional method to increase power has been to enlarge the participant pool, which is both time-consuming and costly.

Unlearn's TwinRCTs offer a solution by amplifying the power of trials without the need for more participants. A case study re-examining a completed Alzheimer’s Disease trial showed that a traditional trial would have needed 23% more participants to match the power of Unlearn's enhanced TwinRCT. This additional recruitment could have delayed enrollment by as much as five months. This increase in power significantly improves the efficiency and accuracy of the updated TwinRCTs, representing a notable advancement in the design and analysis of clinical trials.

Moreover, the new version of TwinRCT has been integrated into TrialPioneer, Unlearn's complimentary web-based tool. This application facilitates collaboration among pharmaceutical and biotech entities, allowing them to explore how different trial design choices impact sample size, statistical power, and enrollment timelines. TrialPioneer currently covers seven major disease categories, with ongoing expansion to include more conditions. The platform also underscores the significant benefits that Unlearn's AI-driven trial designs provide over conventional methods.

Unlearn is a San Francisco-based tech firm that is harnessing AI to streamline medical trials and reduce the trial-and-error aspect of medicine. The company's technology is utilized by top pharmaceutical companies globally to expedite full enrollment and accelerate the delivery of new treatments to patients. Unlearn's approach, which leverages digital twins of participants, is recognized by the European Medicines Agency and complies with FDA guidelines.